Established care
Organ and activity-specific treatment stays central
Hydroxychloroquine, glucocorticoids, immunosuppressants, and approved biologics remain selected around your disease activity and organ involvement.
One diagnosis, many organ patterns
Stem cell therapy for lupus in Istanbul, Turkey
An organ-specific program combining MSC-based immune modulation with your existing lupus care, physician monitoring, and transparent Istanbul pricing.
Conceptual biological visualization
Evidence status
What the evidence can support now
What we add
Cell-based immune modulation
For severe or refractory disease, we coordinate access to MSC studies, transplant programs, and CAR-T research where appropriate.
What we won't promise
A simple, risk-free immune reset
We won't promise a generic infusion that restores the immune system or removes the need for medication. We walk you through the real risks and uncertainty.
A direct answer
The short answer
We offer cell-based immune-modulation protocols for carefully selected, treatment-refractory systemic lupus erythematosus. MSC infusion, autologous hematopoietic stem-cell transplantation, and CAR-T are fundamentally different options, and none replaces your standard lupus or lupus-nephritis care. Results vary between patients and stem cell therapy is not a guaranteed cure.
Start with the phenotype
Your lupus phenotype shapes the plan
Skin and joint disease, nephritis, CNS involvement, blood abnormalities, and cardiopulmonary disease each carry a different risk profile and protocol.
Lupus care never pauses for a package
We keep your specialist team's plan for controlling activity and preventing organ damage running throughout.
- Antimalarial therapy for most suitable patients
- Organ and activity-specific immunosuppressive treatment
- Approved biologics for selected disease patterns
- Kidney, blood, cardiovascular, bone, infection, and pregnancy monitoring
- Shared decisions across rheumatology, nephrology, neurology, hematology, or cardiology as needed
- 01
Lupus nephritis
Proteinuria, kidney function, biopsy class, and response to standard therapy drive urgency and safety.
- 02
Neuropsychiatric lupus
Seizure, stroke, psychosis, neuropathy, and other presentations require specialist evaluation.
- 03
Hematologic disease
Cytopenias, clotting, antiphospholipid syndrome, and bleeding risk affect candidacy.
- 04
Cardiopulmonary disease
Pericarditis, myocarditis, pulmonary hypertension, and lung disease can affect travel safety.
Product and route matter
Three options, kept clearly separate
We name the product and clinical setting so you always know exactly what you're being offered.
- 01
Mesenchymal stromal cells
Usually allogeneic IV products studied for paracrine immune modulation.
Evidence boundaryEarly-phase evidence; we're transparent about current limits.
- 02
Autologous HSCT
Conditioning chemotherapy suppresses the immune system before blood-forming stem cells are returned.
Evidence boundaryCarries infection, infertility, organ toxicity, and treatment-related mortality risk that we review with you in full.
- 03
CAR-T cell therapy
Engineered immune cells target B-cell biology in highly specialized research settings.
Evidence boundaryNot a stem-cell infusion — a distinct, intensive investigational treatment.
- 04
Exosome products
Acellular vesicle products are marketed commercially elsewhere.
Evidence boundaryNo FDA-approved exosome product exists for lupus, and we don't overstate what these can do.
Indexed evidence ledger
The evidence, honestly presented
A six-person safety study and a registered trial show research activity, and we present them as exactly that — not proof of routine benefit.
01 US phase I MiSLE study
Open study- Product
- Single IV dose of allogeneic umbilical-cord MSCs
- Study design
- Early safety study in six women with refractory lupus
- Finding
- Provided feasibility and safety observations for further study.
- Limitation
- Extremely small and uncontrolled; not designed to establish efficacy.
02 MiSLE phase II
Open study- Product
- MSC strategy in moderate to severe lupus
- Study design
- Randomized US clinical trial record
- Finding
- Completed in 2026 with no posted results at the time of review.
- Limitation
- Registration and completion don't establish benefit until results are reported.
03 French phase I dose escalation
Open study- Product
- Allogeneic MSC infusion
- Study design
- Single-center open-label severe refractory SLE study
- Finding
- Focused on feasibility and safety across doses.
- Limitation
- Small early-phase design; not yet suited to routine clinical claims.
Measure what changes
We track your disease activity and organs
Energy and sleep matter, but we always pair them with a validated lupus activity and organ-safety plan.
- 01
Disease activity
SLEDAI, BILAG, flare rate, steroid exposure, and physician global assessment.
- 02
Immune markers
Complement, anti-dsDNA, CBC, and other markers interpreted in clinical context.
- 03
Kidney outcomes
Creatinine, eGFR, urinalysis, proteinuria, sediment, and biopsy context when relevant.
- 04
Patient function
Fatigue, pain, participation, sleep, and quality of life with validated measures.
Clinical review before travel
A multidisciplinary Istanbul evaluation
Your review identifies active organs, current disease control, treatment history, infection risk, and travel stability before any protocol is proposed.
Records to send
- Rheumatology summary, diagnosis, activity, and organ history
- Medication and biologic timeline with response and adverse effects
- CBC, creatinine, eGFR, urinalysis, proteinuria, complements, and anti-dsDNA
- Kidney biopsy, echocardiogram, lung, neurologic, or hematology records when relevant
- Infection, vaccination, pregnancy, clotting, and malignancy history
Reasons to pause
- Active infection, fever, or inadequately evaluated cytopenia
- Unstable nephritis, CNS, cardiac, pulmonary, or thrombotic disease
- Pregnancy or another trial-specific exclusion requiring specialist guidance
- Any proposal to stop lupus medication or call an infusion a risk-free immune reset
Transparent planning
Lupus stem cell therapy cost in Istanbul, Turkey
Your quote names clearly whether it covers an outpatient MSC protocol, a hospital-based procedure, or another intensive intervention, since these carry very different prices and risk profiles.
For context, our general 2026 MSC planning range is $7,000-$18,000. This does not cover HSCT or CAR-T; your quote is itemized to your exact protocol.
- Organ-specific rheumatology and subspecialty review
- Exact intervention, source, dose, route, and release testing
- Hospital, laboratory, infection, and observation requirements
- Medication coordination and longitudinal organ monitoring
Questions patients ask us
- 01
How much does lupus stem cell therapy cost in Turkey?
- 02
Is this MSC infusion, autologous HSCT, CAR-T, or an acellular product?
- 03
How many days will I need in Istanbul for evaluation and treatment?
- 04
How will activity, steroid exposure, kidney function, and flares be tracked with my specialists?
FAQ
Questions about lupus
No, and we won't claim otherwise. Our program focuses on selected refractory disease as an addition to, never a replacement for, proven treatment. Results vary between patients and stem cell therapy is not a guaranteed cure.
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.